Indications
Therapeutic Asset Ratings
13,145 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
spg302
Amyotrophic Lateral Sclerosis
Spinogenix
P2
B
(57)
sr419
Postherpetic Neuralgia
Shanghai SIMR Biotechnology Co., Ltd.
P2
B
(57)
sr750
Trigeminal Neuralgia
Shanghai SIMR Biotechnology Co., Ltd.
P2
B
(57)
Sulfur Hexafluoride
Pancreatic Ductal Adenocarcinoma
Adenocyte, LLC
P2
B
(57)
Suvecaltamide
Parkinson Disease
Jazz Pharmaceuticals
P2
B
(57)
Tabelecleucel
Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
P2
B
(57)
Tacrolimus
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical Center
P2
B
(57)
Tacrolimus
B-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
P2
B
(57)
Tacrolimus
CD4+/CD56+ Hematodermic Neoplasm
Fred Hutchinson Cancer Center
P2
B
(57)
Tacrolimus
GATA2 Deficiency With Susceptibility To MDS/AML
Fred Hutchinson Cancer Center
P2
B
(57)
Tacrolimus
SAMD9L-Related Spectrum And Myeloid Neoplasm Risk
Fred Hutchinson Cancer Center
P2
B
(57)
Tacrolimus
SAMD9-Related Spectrum And Myeloid Neoplasm Risk
Fred Hutchinson Cancer Center
P2
B
(57)
Tacrolimus
Inherited Sideroblastic Anemia
Fred Hutchinson Cancer Center
P2
B
(57)
Tacrolimus
Immunodeficiency Disease
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
B
(57)
Tacrolimus
Lymphoplasmacytic Lymphoma
Masonic Cancer Center, University of Minnesota
P2
B
(57)
Tacrolimus
Myeloid Neoplasm
M.D. Anderson Cancer Center
P2
B
(57)
Tadalafil
Pancreatic Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
B
(57)
Tadalafil
Priapism
Vanderbilt University Medical Center
P2
B
(57)
Tak-062
Celiac Disease
Takeda
P2
B
(57)
Tak-101
Celiac Disease
Takeda
P2
B
(57)
Talazoparib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)
P2
B
(57)
Tarlatamab
Medullary Thyroid Gland Carcinoma
University of Arizona
P2
B
(57)
Tazemetostat
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Malignant Glioma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Rhabdomyosarcoma
National Cancer Institute (NCI)
P2
B
(57)
Showing 3476 to 3500 of 13,145 assets
Previous
Page 140 of 526
Next